Stay updated with breaking news from Clinical Research Programme. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A single dose of the typhoid conjugate vaccine, Typbar TCV®, provides lasting efficacy in preventing typhoid fever in children ages 9 months to 12 years old,
A single dose of the typhoid conjugate vaccine, Typbar TCV®, provides lasting efficacy in preventing typhoid fever in children ages 9 months to 12 years old, according to a new study conducted by...
The University of Maryland, Baltimore (UMB) is the state’s public health, law, and human services university devoted to excellence in professional and graduate education, research, patient care, and public service.
A single dose of the typhoid conjugate vaccine, Typbar TCV®, provides lasting efficacy in preventing typhoid fever in children ages 9 months to 12 years old, according to a new study.
A single dose of the typhoid conjugate vaccine, Typbar TCV, provides lasting efficacy in preventing typhoid fever in children ages 9 months to 12 years old, according to a new study conducted by researchers at University of Maryland School of Medicine's (UMSOM) Center for Vaccine Development and Global Health (CVD) and led by in-country partners at the Malawi-Liverpool Wellcome Trust (MLW) Clinical Research Programme.